SPOTLIGHT -
Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric Indication
The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.